Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%

FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Global state: No clinically important change (as defined by the original studies) · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE DECANOATE changes no clinically important global change compared with ORAL NEUROLEPTICS (very low certainty).

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
RR 0.85 [0.56, 1.27]
1 study · 102 participants
Very low

FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Hospital admission ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Leaving the study early · patients with schizophrenia

FLUPHENAZINE DECANOATE showed no clear difference in leaving the study early compared with ORAL NEUROLEPTICS (low certainty).

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
RR 0.96 [0.73, 1.25]
10 studies · 937 participants
Low

FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 120 participants
Very low

FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE DECANOATE changes extrapyramidal adverse effects ‐ general compared with ORAL NEUROLEPTICS (very low certainty).

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
RR 0.47 [0.24, 0.91]
3 studies · 259 participants
Very low

FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Death ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Relapse · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE DECANOATE changes relapse compared with ORAL NEUROLEPTICS (very low certainty).

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
RR 1.46 [0.75, 2.83]
6 studies · 419 participants
Very low